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Abstract
Background Chronic low-grade systemic inflammation is
a key component in atherogenesis. Decreased heart rate
variability (HRV), a strong predictor of cardiovascular
events, has been associated with elevations in circulating
levels of C-reactive protein (CRP), interleukin (IL)-6, and
fibrinogen in apparently healthy individuals. We investi-
gated whether decreased HRV is associated with inflam-
matory markers in patients with coronary heart disease
(CHD).
Methods We studied the relationship between HRV and
CRP, IL-6, and fibrinogen in 862 outpatients with CHD.
All participants provided fasting blood samples and
underwent 24-h ambulatory monitoring to assess time-
domain measures of HRV (MeanNN, SDNN, SDANN, and
RMSSD). Regression analyses were adjusted for age, sex,
ethnicity, body mass index, smoking, diabetes, beta blocker
use, and cardiopulmonary history.
Results MeanNN, SDNN, and SDANN were significantly
and inversely associated with CRP and IL-6 levels in age-
adjusted models and after adjustment for all covariates
(p B 0.02). MeanNN, SDNN, and SDANN were also
inversely associated with fibrinogen levels in age-adjusted
models (p \ 0.03), but not significantly so in multivari-
able-adjusted models. Reduced vagal modulation of heart
rate (RMSSD) was not significantly associated with any
inflammatory measures.
Conclusions Reduced cardiac autonomic control is asso-
ciated with increased systemic inflammation in patients
with stable CHD. This relationship was largely indepen-
dent of important covariates.
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Introduction
Chronic low-grade systemic inflammation is involved in all
stages of coronary atherogenesis, from initial endothelial
dysfunction to plaque rupture and clinical manifestation of
acute atherothrombotic events [1]. Meta-analyses show that
elevated levels of biomarkers of systemic inflammation,
particularly C-reactive protein (CRP), interleukin (IL)-6,
and fibrinogen, predict incident coronary heart disease
(CHD), independent of traditional cardiovascular risk fac-
tors [2–4]. Inflammatory biomarkers are also predictive of
cardiovascular outcomes in patients with established CHD
[5]. For instance, in patients with stable CHD, increased
CRP levels predict unstable angina, recurrent non-fatal
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myocardial infarction (MI), and fatal coronary events [6–
8]. Elevated fibrinogen levels predict non-fatal MI and
cardiovascular death in patients with chronic CHD [9], and
elevated IL-6 during unstable angina increases the risk of
in-hospital coronary events [10].
Additional research suggests a relationship between
compromised autonomic regulation of the heart, as asses-
sed by decreased heart rate variability (HRV), and
increased systemic inflammation [11]. In apparently heal-
thy individuals of varying age, several indices of decreased
HRV have been associated with elevated circulating levels
of CRP [12–19], IL-6 [18–20], and fibrinogen [15, 21],
independent of covariates. In patients with stable CHD,
however, the relationship between HRV and levels of CRP,
IL-6, and fibrinogen has not been well studied. Previous
studies have been small [22–26], mostly restricted to
women [26, 27], and generally limited to one measure of
inflammation [28]. Therefore, we sought to evaluate the
relationship between cardiac autonomic control and three
measures of systemic inflammation in a large sample of
women and men with stable CHD. Our specific hypothesis
was that decreased HRV would be associated with elevated
circulating levels of CRP, IL-6, and fibrinogen.
Materials and methods
Study participants and recruitment
The Heart and Soul Study is a prospective cohort study of
health outcomes in outpatients with stable CHD. The
details of eligibility and enrollment have previously been
prescribed [29]. In brief, between 9/2000 and 12/2002, a
total of 1,024 participants were recruited using adminis-
trative databases from two Department of Veterans Affairs
Medical Centers (San Francisco, California and Palo Alto,
CA, USA), one university medical center (University of
California, San Francisco, USA), and nine public health
clinics in the Community Health Network of San
Francisco.
Patients were eligible to participate if they had at least
one of the following: a history of MI or coronary revas-
cularization, angiographic evidence of C50% stenosis in
one or more major coronary vessels, or evidence of exer-
cise-induced ischemia by treadmill or nuclear testing.
Patients were not eligible if they had an acute coronary
syndrome within the past 6 months, could not walk one
block, or were planning to move from the area within
3 years.
All participants completed a daylong study appointment
at the San Francisco Veterans Affairs Medical Center in
California that included a comprehensive health interview,
a medical history questionnaire, and 24-h ambulatory
Holter monitoring to determine HRV. Particularly, for the
purpose of the present study, the fasting blood samples for
the determination of biomarkers were drawn first thing in
the morning (around 9 am), a few hours before the Holter
monitoring was started on the same day (around 3 pm). We
excluded 151 patients because they had a paced rhythm,
atrial fibrillation, or their Holter ECG was unable to be
collected, and 11 patients for whom we did not have fasting
blood samples, leaving 862 participants for this cross-sec-
tional analysis. All participants provided written informed
consent to this protocol which was approved by the insti-
tutional review board at each of the sites.
Additional participant characteristics
Sociodemographic factors, medical history, smoking sta-
tus, and alcohol use [30] were determined by question-
naire. We measured weight and height to calculate the
body mass index (BMI, kg/m2) Participants were con-
sidered to be physically active if they reported being
somewhat, very, or extremely active (vs. not at all or a
little active) in the last month. Participants were
instructed to bring their medication bottles to the study
appointment, and study personnel recorded current med-
ications. We measured resting blood pressure by means
of standard sphygmomanometry and assayed serum lipids
after a 12-h fast.
Heart rate variability
Heart rate variability parameters were obtained via 3-
channel 24-h ambulatory Holter electrocardiographic
recording as recommended by the Task Force of the
European Society of Cardiology and the North American
Society of Pacing and Electrophysiology [31]. Tapes were
scanned at 500 times real time, and electrocardiography
data were digitized at a sampling frequency of 128 Hz.
Computer software (General Electric Medical System
Software for Holter Analysis, GE Healthcare, Waukesha,
WI, USA) was used to detect and label each QRS complex
using beats with normal morphologic characteristics and a
cycle length less than 20% duration of the preceding cycle
length. An independent and blinded reviewer processed all
Holter ECGs and modified any inappropriate computer
labels, with particular focus on periods with the highest and
lowest average RR intervals. The annotated QRS data were
processed to allow time-domain characterization, including
the mean of all normal-to-normal intervals (MeanNN in
ms), the standard deviation of all NN intervals (SDNN in
ms), the standard deviation of the mean of NN intervals in
all 5-min segments of a 24-h recording (SDANN in ms),
and the square root of the mean squared differences of
successive NN intervals (RMSSD in ms).
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Inflammatory biomarkers
Participants were instructed to fast for 12 h, not to smoke
for 5 h before the investigation, and not to take aspirin for
1 week. Patients were allowed to take all other medications
as prescribed. Serum and plasma aliquots were stored at -
70C until analyzed.
Interleukin-6
We used the Quantikine HS IL-6 Immunoassay (R&D
Systems, Minneapolis, MN, USA) to determine the con-
centration of serum IL-6 with a reportable range of
0.43–8.9 pg/mL. The inter-assay CV is 6.5–9.6%, and the
intra-assay CV is 6.9–7.8%.
Fibrinogen
Plasma fibrinogen concentrations were determined by the
Clauss method. Dilutions of plasma standard of known
fibrinogen concentrations are clotted with a high concen-
tration of thrombin. The participant’s clotting time is pro-
portional to his or her plasma fibrinogen concentration. The
standard assay range is 60–10,000 mg/dL, and the inter-
and intra-assay CVs are both \3%.
C-reactive protein
Serum high-sensitivity CRP (hs-CRP) was determined
using the Roche Integra assay or (owing to a change in the
laboratory) the Beckman Extended Range assay in the
remaining. Results from these two assays were highly
correlated (r = 0.99 in 185 participants). The Roche Inte-
gra hs-CRP assay has an inter-assay coefficient of variation
(CV) of 3.2%. Lowest limit of detection is 0.25 mg/L. The
Beckman Extended Range hs-CRP assay has an inter-assay
CV of B6.7%, an intra-assay CV of \6.2%, and a report-
able range of 0.20–1,140 mg/L.
Statistical analysis
Level of significance was set at p \ 0.05 (two-tailed). For
descriptive purposes, differences in characteristics between
participants with SDNN \ 100 ms (low HRV) and those
with SDNN C 100 ms (normal HRV) were compared
using Student’s t test for continuous variables and v2 test
for dichotomous variables. This cut-off for SDNN, a
measure of total HRV, was previously predictive for
mortality in patients after MI [31, 32]. Values of CRP, IL-
6, and fibrinogen were log transformed to approximate
normal distributions.
Multivariate linear regression analysis was applied to
test for a relationship between HRV measures and
inflammatory factors. Two models were computed. Model
1 adjusted for age, and Model 2 additionally adjusted for
sex, ethnicity (White vs. non-White), current smoking (yes
vs. no), BMI, use of beta blockers, history of diabetes,
history of chronic heart failure (CHF), and history of
chronic obstructive pulmonary disease (COPD). We
selected these covariates because they were previously
shown to be associated with HRV in different studies [31]
and also in an earlier analysis of subjects from the Heart
and Soul Study [33].
Results
Patient characteristics
Table 1 shows the comparison in characteristics between
the 264 patients with low HRV and the 598 patients with
normal HRV as per a cutoff of 100 ms for SDNN [31].
Patients with low HRV were more likely to be female and
of non-White ethnicity. Relative to patients with normal
HRV, those with low HRV were more likely to have CHF,
COPD, and diabetes, and to have higher BMI. There were a
significantly higher number of smokers in the group with
low HRV.
Relationship between heart rate variability
and inflammatory measures
Table 2 shows the partial correlation coefficients with
significance level for the relationship between the various
HRV measures and inflammatory factors in Model 1 that
adjusted for age and in the fully adjusted Model 2 with
covariates age, sex, ethnicity, smoking, BMI, use of beta
blocker, history of CHF, COPD, and diabetes.
Model adjusting for age
In Model 1, nearly all of the HRV measures (i.e., Mean
NN, SDNN, and SDANN) showed a significant inverse
relationship with CRP, IL-6, and fibrinogen levels
(Table 2). Exceptions were seen for RMSSD which was
not significantly associated with any of the three inflam-
matory measures. For illustrative purposes, Fig. 1 depicts
the age-adjusted levels of IL-6, fibrinogen, and CRP in
patients with low (SDNN \ 100) and in those with normal
HRV (all p \ 0.05).
Fully adjusted model
After adjusting for covariates in Model 2, the significance
of results from Model 1 was maintained for CRP and IL-6
levels. However, the previously significant relationships
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with fibrinogen were no longer significant. Virtually in all
models, older age, female sex, higher BMI, positive history
of CHF, positive history of COPD, and current smoking
were independent predictors of elevated CRP levels.
Likewise, greater age, male sex, higher BMI, positive
history of CHF, and current smoking were independent
predictors of elevated IL-6 levels in most models. Older
age, higher BMI, history of diabetes, and current smoking
were found to be independent predictors of elevated
fibrinogen levels in most models.
Because age, BMI, and smoking status were indepen-
dent predictors of CRP, IL-6, and fibrinogen, we addi-
tionally computed interaction terms for the various HRV
measures with age, BMI, and smoking. However, we found
no evidence that the relationship between decreased HRV
and inflammation was moderated by age, BMI, or current
smoking (all p values for interaction [0.10).
Discussion
Cross-sectional studies in healthy populations have clearly
demonstrated an independent association between HRV
and both CRP and IL-6 levels [12–20]. However, until
now, the association between HRV and inflammation in
patients with CHD has been less clear. The largest prior
study of patients with CHD found an association between
time-domain measures of HRV and CRP in a sample of
269 patients with clinically suspected CAD who were
referred for angiography [28]. Our study expands these
findings by demonstrating a robust inverse association
between time-domain measures of HRV and two inflam-
matory biomarkers (i.e., CRP and IL-6) in a large sample
of 862 outpatients with stable CHD. Together with the
results of prior studies, these findings make it clear that low
HRV is indeed associated with inflammation in patients
with stable CHD. We further found that HRV is inversely
associated with fibrinogen, although less consistently so
than with CRP and IL-6, when taking covariates into
account. Nevertheless, our findings concur with studies in
healthy populations [15, 21], depressed CHD patients [22],
and women patients with CHD [27], all suggesting an
inverse relationship between HRV and fibrinogen.
Research shows that the vagus nerve curtails inflam-
matory activity of peripheral tissue macrophages via an
anticholinergic pathway [34]. The vagus nerve also informs
the brain about peripheral inflammation resulting in acti-
vation of the hypothalamic pituitary adrenal axis with the
subsequent increase in peripheral cortisol level having
systemic anti-inflammatory effects [35]. HRV measures
indicating vagal modulation of heart rate (e.g., RMSSD)
thus might play a role in systemic inflammation related to
atherosclerosis and CHD [36]. However, we found no
evidence for a significant relationship between RMSSD, an
index of respiratory sinus arrhythmia, and inflammation.
One explanation might be that some measures of vagal
cardiac control tend to decline with age and thus, even
when controlling for age statistically, RMSSD might not
reliably reflect vagal modulation of heart rate in our group
Table 1 Characteristics of participants with low (SDNN \ 100 ms)
versus normal (SDNN C 100 ms) heart rate variability
Variable Low HRV
(n = 264)
Normal
HRV
(n = 598)
p value
Demographic factors
Age (years) 66 ± 10 69 ± 11 0.235
Male sex 204 (77) 500 (84) 0.027
High school graduate 226 (86) 524 (88) 0.416
Living alone 88 (33) 219 (37) 0.353
Ethnicity
White 137 (52) 363 (61) 0.025
Black 60 (23) 88 (15)
Asian 32 (12) 73 (12)
Other 34 (13) 74 (12)
Cardiac history
Prior myocardial infarction 143 (55) 323 (54) 0.937
Coronary artery bypass surgery 106 (40) 207 (35) 0.112
Percutaneous revascularization 95 (36) 241 (40) 0.232
Comorbid conditions
Hypertension 199 (75) 416 (70) 0.095
Stroke 42 (16) 83 (14) 0.447
Chronic heart failure 57 (22) 80 (13) 0.003
Chronic obstructive
pulmonary disease
57 (22) 79 (13) 0.002
Metabolic factors
History of diabetes 102 (39) 119 (20) \0.001
Systolic blood pressure (mmHg) 135 ± 22 133 ± 21 0.189
Low-density lipoprotein
cholesterol (mg/dL)
105 ± 35 104 ± 32 0.538
High-density lipoprotein
cholesterol (mg/dL)
46 ± 15 46 ± 14 0.937
Body mass index (kg/m2) 28.9 ± 5.8 28.1 ± 4.8 0.026
Health habits
Current smoking 64 (24) 103 (17) 0.017
Alcohol score 2.4 ± 2.5 2.2 ± 2.4 0.147
Physically active 156 (59) 392 (66) 0.075
Medications
Beta blocker 160 (61) 353 (59) 0.664
Statin 167 (63) 393 (66) 0.485
Angiotensin-converting
enzyme inhibitor
123 (47) 296 (49) 0.431
Aspirin 216 (82) 477 (80) 0.484
Data are given as absolute values with percent values in parentheses
or mean ± SD
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Table 2 Association of heart rate variability measures with inflammatory markers
HRV measure Log interleukin-6 Log fibrinogen Log C-reactive protein
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
r p value r p value r p value r p value r p value r p value
Mean NN (ms) -0.11 0.002 -0.08 0.017 -0.08 0.026 -0.03 0.415 -0.16 \0.001 -0.11 0.003
SDNN (ms) -0.19 \0.001 -0.14 \0.001 -0.12 0.001 -0.06 0.105 -0.14 \0.001 -0.08 0.016
SDANN (ms) -0.18 \0.001 -0.14 \0.001 -0.11 0.001 -0.05 0.152 -0.14 \0.001 -0.08 0.020
RMSSD (ms) -0.02 0.568 -0.02 0.577 -0.03 0.431 -0.01 0.788 \0.01 0.965 \0.01 0.918
Model 1: adjusted for age
Model 2: adjusted for age, sex, race (White vs. non-White), body mass index, use of beta blockers, history of diabetes, history of congestive heart
failure, history of chronic obstructive pulmonary disease, and current smoking
Shown are partial correlation coefficients with p values
Fig. 1 Mean ± SE age-
adjusted levels of inflammatory
markers in patients with low
(SDNN \ 100) versus normal
(SDNN C 100) heart rate
variability. The bar graphs (a–
c) illustrate the age-adjusted
mean ± SEM levels of
interleukin-6, fibrinogen, and C-
reactive protein levels in
patients with SDNN \ 100 ms
(low heart rate variability,
HRV) compared to those with
SDNN C 100 ms (normal
HRV). Data are given in
original units (all p \ 0.05)
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of relatively older individuals. To support this notion, our
group found in middle-aged healthy subjects an inverse
relationship between night-time RMSSD and levels of both
CRP [17] and fibrinogen [21] and between HF power
(another index of vagal cardiac control) and IL-6 [20] after
controlling for covariates. It is also likely that CHD itself
affects RMSSD through erratic rhythms as shown in older
subjects with cardiovascular disease [37].
The cross-sectional nature of our study precludes any
inference about the causal direction of the relationship
between HRV and inflammation. Therefore, our findings
may suggest that inflammation contributes to the poor
prognosis associated with low HRV in patients with CHD
on one hand. On the other hand, the findings may also
suggest that low HRV contributes to poor CHD prognosis
associated with inflammatory markers. In subjects with no
apparent heart disease, the combination of decreased HRV
and increased CRP has been shown to synergistically
predict future risk of first-time MI and all-cause mortality
[38]. Decreased HRV also predicted cardiovascular death
during 13-year follow-up in patients with mild–moderate
heart failure [39], and inflammation (incl. CRP) has been
shown to be associated with markers of heart failure
severity [40]. However, it is as yet unclear whether
decreased HRV leads to inflammation or vice versa. Nev-
ertheless, the sustained increase in IL-6 with decreased
HRV might further plaque progression and instability,
thereby increasing the risk of plaque rupture and coronary
thrombosis [41, 42]. The HRV-associated inflammation
also seems to be involved in the acute phase of a CHD
event. This is evidenced by inverse associations between
HRV and both IL-6 and CRP in patients with acute coro-
nary syndromes [43, 44], whereby patients with compli-
cated acute coronary syndromes show particularly high
levels of proinflammatory cytokines, including IL-6 [45].
One possible limitation of our study is that we pooled data
from diabetics and non-diabetics. Although we adjusted
our final model for diabetes, diabetics with their neuropa-
thy and non-diabetics have different conditions affecting
HRV, which might also affect results.
In conclusion, we have substantiated the current
assumption of an inverse relationship between HRV and
chronic low-grade systemic inflammation in patients with
stable CHD. The independent relationship between com-
promised cardiac autonomic control and increased circu-
lating levels of CRP, IL-6, and to a lesser extent fibrinogen,
might play an important role in the progression of CHD
and recurrent events.
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